Clinical Trials Directory

Trials / Completed

CompletedNCT04044079

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients: a Randomized Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To compare the effectiveness of vaginal dinoprostone and vaginal misoprostol with placebo in minimizing the pain experienced by postmenopausal patients during diagnostic office hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

Detailed description

hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, fibroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. Cervical ripening is made possible by the use of medication through different routes. The most commonly used agent is misoprostol, a synthetic prostaglandin E1 (PGE1) analog that is frequently administered in off-label use in obstetrics and gynecology for medical abortion, labor induction, endometrial biopsy, dilatation and curettage, intrauterine device insertion, myomectomy, postpartum hemorrhage, and cervical ripening. In contrast, dinoprostone, a natural PGE2, is mostly used in obstetrics for cervical ripening and the stimulation of uterine contractions to induce labor.

Conditions

Interventions

TypeNameDescription
DRUGDinoprostone1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
DRUGMisoprostolMisoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
DRUGPlaceboone tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.

Timeline

Start date
2019-08-20
Primary completion
2020-01-10
Completion
2020-02-10
First posted
2019-08-02
Last updated
2020-09-01

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04044079. Inclusion in this directory is not an endorsement.

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients (NCT04044079) · Clinical Trials Directory